- Home
- WMB vs PFE Comparison
WMB vs PFE Comparison
Compare WMB & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WMB | PFE |
|---|---|---|
| Founded | 1908 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.6B | 147.6B |
| IPO Year | 2002 | 2013 |
Fundamental Metrics
Financial Performance| Metric | WMB | PFE |
|---|---|---|
| Price | $71.64 | $28.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 14 |
| Target Price | ★ $77.41 | $29.29 |
| AVG Volume (30 Days) | 6.0M | ★ 32.6M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | 2.86% | ★ 6.55% |
| EPS Growth | ★ 17.58 | N/A |
| EPS | ★ 1.38 | 0.43 |
| Revenue | $11,950,000,000.00 | ★ $62,579,000,000.00 |
| Revenue This Year | $6.97 | N/A |
| Revenue Next Year | $9.85 | N/A |
| P/E Ratio | ★ $51.51 | $66.44 |
| Revenue Growth | ★ 13.78 | N/A |
| 52 Week Low | $56.09 | $23.59 |
| 52 Week High | $80.08 | $28.75 |
Technical Indicators
Market Signals| Indicator | WMB | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 69.03 |
| Support Level | $69.47 | $24.90 |
| Resistance Level | $74.36 | $28.75 |
| Average True Range (ATR) | 1.87 | 0.52 |
| MACD | -0.11 | 0.13 |
| Stochastic Oscillator | 29.48 | 81.71 |
Price Performance
Historical ComparisonAbout WMB Williams Companies Inc. (The)
Williams operates the Transco pipeline, which connects the Gulf Coast to the Northeast United States. It has additional natural gas transmission pipelines connecting the Rockies to the Pacific Northwest and midcontinent. At the field level, it operates substantial gathering and processing assets in Appalachia and other basins. The company has also struck several power supply agreements.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.